Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Sept 2015

Theys Kristof, Abecasis Ana, Libin Pieter, Gomes Perpe Tua, Cabanas Joaquim, Camacho Ricardo J, Van Laethem Kristel

Abstract excerpt

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolutegravir activity after raltegravir use, and identified individual mutational patterns for which uncertainty exists...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Treatment Failure

Source

Identifiers

PMID: 26305833
DOI: 10.1016/j.jcv.2015.07.311

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.PMID 26305833Read ↗

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.Semantic proximity Read ↗

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.Semantic proximity Read ↗

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.Semantic proximity Read ↗

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.Semantic proximity Read ↗

Discrepancies of HIV-1 reverse transcriptase resistance interpretation of insertions and deletions between two genotypic algorithms.Semantic proximity Read ↗

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapySemantic proximity Read ↗

Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis.Semantic proximity Read ↗

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.